<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001903'>Anemia</z:hpo> is a widely prevalent complication among <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>At the time of diagnosis, 30% to 40% of patients with non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and up to 70% of patients with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> are anemic; rates are higher among persons with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Among patients with solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> or <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, up to half develop <z:hpo ids='HP_0001903'>anemia</z:hpo> following chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>For almost 2 decades, erythropoiesis-stimulating agents (ESAs) were the primary treatment for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>However, reassessments of benefits and risks of ESAs for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-associated <z:hpo ids='HP_0001903'>anemia</z:hpo> have occurred internationally </plain></SENT>
<SENT sid="5" pm="."><plain>We reviewed guidelines and notifications from regulatory agencies and manufacturers, reimbursement policies, and utilization for ESAs in the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> settings within the United States, Europe, and Canada </plain></SENT>
<SENT sid="6" pm="."><plain>In 2008 the US Food and Drug Administration (FDA) restricted ESAs from <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients seeking cure </plain></SENT>
<SENT sid="7" pm="."><plain>Reimbursement is limited to <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels &lt; 10 g/dL </plain></SENT>
<SENT sid="8" pm="."><plain>In the United States, ESA usage increased 340% between 2001 and 2006, and decreased 60% since 2007 </plain></SENT>
<SENT sid="9" pm="."><plain>The European Medicines Agency (EMEA) recommended that ESA benefits do not outweigh risks </plain></SENT>
<SENT sid="10" pm="."><plain>In Europe between 2001 and 2006, ESA use increased 51%; since 2006, use decreased by 10% </plain></SENT>
<SENT sid="11" pm="."><plain>In 2009, Canadian manufacturers recommended usage based on patient preferences </plain></SENT>
<SENT sid="12" pm="."><plain>In Canada in 2007, approximately 20% of anemic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients received ESAs, a 20% increase since 2004 </plain></SENT>
<SENT sid="13" pm="."><plain>In contrast to Europe, where ESA use has increased over time, reassessments of ESA-associated safety concerns in the United States have resulted in marked decrements in ESA use among <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
</text></document>